A Multiple Sclerosis Doctor Explains The Ins and Outs of Lemtrada for RRMS Patients in a Series of YouTube Videos

Lemtrada Stroke Lawsuit News

Lemtrada patients will be more informed and make better decisions from having viewed this series of RRMS videos

Monday, June 22, 2020 - Patients try Lemtrada when they have no other options, and some patients have had mixed experiences with the drug. Patients give Lemtrada a try only after they have given two or more late-stage medications a try and have failed. Lemtrada is an intravenous, disease-modifying therapy (DMT) given to patients that have relapse-remitting multiple sclerosis (RRMS) only after they have agreed in writing with their physicians. The agreement explains in excruciating detail the potential for harm to their health that includes instant death. Some Lemtrada patients feel that they have no other alternative and that they have no choice. When an RRMS patient is contemplating taking such a toxic and life-threatening medication, it is good to get all of the facts so that the patient can make an informed decision.

According to Health Grades.com, Dr. Aaron Boster, MD is a Neurology Specialist in Columbus, OH and has over 18 years of experience in the medical field. Doctor Boster has produced a casual yet highly informative YouTube video while waiting in the car for his son to take a piano lesson. The video outlines the basics of Lemtrada and is a great educational tool for patients that want to know more about their upcoming treatments. Lemtrada attorneys offer a free consultation with no obligation to file a claim.

According to Dr. Bolster, Lemtrada is administered in two doses, one five consecutive day infusions and the other three days, one year apart. A Lemtrada patient is required to see their physician every three months and to have a blood workup and urine testing every month for four years after their first Lemtrada treatment, mostly to check for the early signs of one of the many life-threatening side effects of the drug. A brain MRI is taken at the sixth month to establish a current baseline from which to work. The patient is reimaged annually after that. If during these four years the patient relapses and has a new MS episode or two spots show up on the MRI, the physician will speak with the patient to reassess where they stand and the best course of action going forward, possibly to include the third round of Lemtrada given over three days. Another option would be to do nothing or to switch drugs. The doctor's recommendation depends on the individual patient's RRMS reactions before and after taking Lemtrada. The doctor may recommend a third round of treatments if a patient was performing well and had no new brain lesions. The contrary is true if the patient never really showed benefits relative to Lemtrada's side effects. Statistics show that about half of all Lemtrada patients need a third round of infusion. Around 10% require the fourth course of Lemtrada.

View more of Dr. Bolster's video outlined above at https://www.youtube.com/watch?v=L-7UXhtpNQE. The Dr. has produced a serious of informative MS videos that include the latest information for RRMS patients regarding the risk given the global health pandemic in which we find ourselves.

More Recent Lemtrada Stroke Lawsuit News:

No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.